Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia

Rok, strany: 2015, 805 - 811

Presented are results of allogeneic hematopoietic stem cell transplantations (HSCTs) in 13 patients with high-risk acute lymphoblastic leukemia (ALL) in the first complete remission after a reduced intensity conditioning combining fludarabine (150 mg/m2) and melphalan (140 mg/m2) with thymoglobulin (4.5 mg/kg). The immunosuppressive effect of T-cell depletion reducing the risk of graft-versus-host disease (GVHD) and non-relapse mortality was compensated by early initiation of reduction and withdrawal of prophylactic immunosuppression aimed at maintaining effective immunological antileukemic control. The median post-transplant follow-up was 23 (range, 10-65) months. Stable engraftment of donor’s hematopoiesis was achieved in all patients. Acute GVHD was observed in two cases (15.4%); the chronic form was not noted. Two patients (15.4%) relapsed with ALL at 3 and 16 months after transplantation. During the above post-transplant follow-up, all 13 recipients were alive, with a probability of 2-year disease-free survival of 76.9% (95% CI 51-100%). Although the results were obtained with a small pilot study group it may be assumed that, given the prognostic risk of most patients and the nearly 2-year median post-transplant follow-up, the approach may be considered as an alternative to HSCTs after traditional myeloablative or reduced conditioning regimens with standard GVHD prophylaxis. Keywords: acute lymphoblastic leukemia, allogeneic hematopoietic stem cell transplantation, fludarabine, melphalan, thymoglobulin, graft-versus-host disease prophylaxis

ISO 690:

Raida, L., Rusinakova, Z., Szotkowska, R., Kuba, A., Faber, E., Rohon, P., Szotkowski, T., Hubacek, J., Pikalova, Z., Jarosova, M., Divoka, M., Indrak, K., Langova, K., Skoumalova, I., Papajik, T. 2015. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia. In NEOPLASMA, vol. 62, no.5, pp. 805-811. 0028-2685.

APA:

Raida, L., Rusinakova, Z., Szotkowska, R., Kuba, A., Faber, E., Rohon, P., Szotkowski, T., Hubacek, J., Pikalova, Z., Jarosova, M., Divoka, M., Indrak, K., Langova, K., Skoumalova, I., Papajik, T. (2015). Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia. NEOPLASMA, 62(5), 805-811. 0028-2685.